[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"WellSpan Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":165},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,39,56,90,113,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100555098","point-of-care-ultrasound-for-the-detection-of-esophageal-food-bolus-100555098",false,"NCT06507670","Point of Care Ultrasound for the Detection of Esophageal Food Bolus","Eligibility (CASES)\n\n* Inclusion criteria:\n\n  1. Age ≥18 years\n  2. Signs and symptoms of esophageal food bolus or foreign body\n* Exclusion criteria:\n\n  1. Prior esophageal surgery\n  2. History of head\u002Fneck cancer\n  3. Incarcerated individuals\n  4. Individuals unable to provide consent\n  5. Clinical instability or airway compromise\n\nEligibility (CONTROLS)\n\n* Inclusion criteria:\n\n  1. Age ≥18 years\n  2. NO signs or symptoms of esophageal food bolus or foreign body\n  3. Age\u002FSex match to previously enrolled case subject\n* Exclusion criteria:\n\n  1. Prior esophageal surgery\u002Fdilation\u002Fpathology\n  2. History of head\u002Fneck cancer\n  3. Incarcerated individuals\n  4. Individuals unable to provide consent\n  5. Clinical instability or airway compromise\n  6. Presentation involving any of the following symptoms:\n* Nausea\u002Fvomiting\n* Diarrhea\n* Abdominal pain\n* Chest pain\n* Shortness of breath\n* Dysphagia\u002Fodynophagia\n* Cough",true,"ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","OBSERVATIONAL","This will be a prospective, observational, case-control study of adult patients presenting to the WellSpan York Hospital Emergency Department (YHED) with signs and symptoms of esophageal food or foreign body impaction. Point of care ultrasound (POCUS) will then be performed by a trained emergency physician to collect ultrasound data, including the presence or absence of direct visualization food bolus\u002Fforeign body, as well as secondary markers of dilatation, such as maximal esophageal area. Investigators will also enroll an age\u002Fsex-matched control group of asymptomatic individuals to establish baseline esophageal measurements.\n\nPatients will otherwise receive medical treatment per standard of care. Subsequent interventions will also be documented, including glucagon, carbonated beverages, and esophagogastroduodenoscopy (EGD). If patients remain in the ED and improve without need for EGD they will undergo repeat ultrasound. Chart review at 1 month will be performed to establish results of EGD including improvement, recurrence, or presence of pathologic abnormalities. The investigators aim to establish normal and abnormal parameters to aid in the diagnosis of esophageal food impactions to predict need for definitive EGD management.",[24,25],"Esophageal Foreign Body","Esophageal Obstruction","RECRUITING","2026-06-02",{"date":29,"type":30},"2026-06-03","ACTUAL",{"date":32,"type":30},"2024-07-01",{"date":34,"type":20},"2027-03-01",{"name":36,"class":37},"WellSpan Health","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":50,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":38},"100443148","point-of-care-ultrasound-in-predicting-adverse-outcomes-in-emergency-department-patients-with-acute-pulmonary-embolism-100443148","NCT05050617","Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism","Inclusion Criteria:\n\n* Age \\>= 18 years of age\n* ED diagnosis of acute pulmonary embolism with identification on CT imaging\n\nExclusion Criteria:\n\n* Age \\\u003C18 years of age\n* Inability to provide informed consent\n* Incarceration\n* Current PE previously diagnosed prior to index ED visit",{"count":46,"type":20},250,"This study is an observational, prospective study examining the role point-of-care echocardiography of predicting short term adverse outcomes in emergency department patients with acute pulmonary embolism.\n\nThe primary objective is to assess the diagnostic performance of ultrasound-guided measures of right ventricular dilation (RVD) and strain in predicting clinical outcomes in acute PE.\n\nThe secondary objective is to investigate the utility of combining ultrasound-guided measures of RVD and the pulmonary embolism severity index (PESI) score in predicting adverse outcomes in acute PE.",[49],"Pulmonary Embolism",{"date":29,"type":30},{"date":52,"type":30},"2021-09-09",{"date":54,"type":20},"2026-12",{"name":36,"class":37},{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":64,"targetDuration":66,"studyType":21,"phases":4,"briefSummary":67,"conditions":68,"keywords":75,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100626286","wellspan-thrive-cancer-qol-study-100626286","NCT07433660","WellSpan-THRIVE Cancer QOL Study","WellSpan Study of Tracking Health and Resilience to Improve the Vitality of Individuals Experiencing Cancer [WellSpan-THRIVE]","THRIVE","Inclusion Criteria:\n\n* Age 18 years and above\n* Primary cancer diagnosis (newly diagnosed within the past 6 months)\n* Able to sign informed consent.\n\nExclusion Criteria:\n\n* Patients with age\\\u003C18 years,\n* Patients with primary non-melanoma skin, neurological malignancies (Brain or brain metastases), and primary hematological malignancies.\n* Patients with severe cognitive impairment, unable to sign informed consent or unable to complete quality of life questionnaire.\n* Patients with life expectancy of \\\u003C90 days, in the opinion of treating investigator.",{"count":65,"type":20},1000,"24 Months","Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social relationships. While many studies have examined factors that influence quality of life; such as age, type and stage of cancer, and treatment-related symptoms; there is still a need for tools that more fully reflect patients' lived experiences.\n\nThis study aims to develop and implement a patient-centered quality of life (QOL) survey designed specifically for individuals with cancer. By directly involving patients in sharing what matters most to them, the survey seeks to provide a more complete and accurate understanding of how cancer and its treatment affect daily life. The results will help patients, families, and healthcare providers better identify needs, guide supportive care, and improve overall well-being throughout the cancer journey.",[69,70,71,72,73,74],"Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment\u002FCare Regimen; i.e. Curative, Life-extending, or Palliative","Cancer (Solid Tumors)","Cancer (With or Without Metastasis)","Cancer - Ovarian","Cancer Abdomen","Cancer (Advanced Stage)",[76,77,78,79,80],"Cancer","Quality of Life","QOL","Registry","Patient","2026-02-26",{"date":83,"type":30},"2026-03-02",{"date":85,"type":20},"2026-02",{"date":87,"type":20},"2031-12",{"name":36,"class":37},5,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":38},"100496755","ultrasound-guided-serratus-anterior-plane-block-for-rib-fractures-100496755","NCT05748366","Ultrasound Guided Serratus Anterior Plane Block for Rib Fractures","Ultrasound Guided Serratus Anterior Plane Block Versus Standard Therapy for Analgesic Relief of Rib Fractures in the Emergency Department","Inclusion Criteria:\n\n* Age \\>18 years\n* \\>1 Unilateral, acute rib fractures diagnosed on x-ray or CT imaging\n* Patient presenting to the WellSpan York Hospital ED\n* Patient requiring IV analgesia or oral opioid to control pain related to rib fractures\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Inability to provide informed consent\n* Allergy to local anesthesia\n* Subsequent visit for rib fractures\n* Patients taken emergently to the OR or discharged from the ED\n* Significant distracting injuries\u002Fpolytrauma that would not be expected to be responsive to analgesia from SAPB and confound pain scores, i.e. long bone fractures, intraabdominal injuries, etc.",{"count":98,"type":20},60,"INTERVENTIONAL",[101],"NA","This study is a single center, randomized controlled trial examining the effect of serratus anterior plane block (SAPB) on pain, PIC scores and other clinical outcomes in emergency department patients with multiple rib fractures in comparison to the use of analgesic medication alone.\n\nObjectives\n\n1. Compare SAPB performed in the ED setting to analgesic medication alone with regard to pain, respiratory status and PIC score of patients with multiple rib fractures.\n2. Assess the safety and feasibility of performing ultrasound-guided SAPB in the ED.\n3. Evaluate outcomes of patients receiving the SAPB in the ED including amount of analgesic medications used, level of care required, need for upgrading level of care, and length of stay.",[104],"Rib Fracture Multiple","2025-07-15",{"date":107,"type":30},"2025-07-18",{"date":109,"type":30},"2023-03-31",{"date":111,"type":20},"2027-06-30",{"name":36,"class":37},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":99,"phases":121,"briefSummary":123,"conditions":124,"keywords":129,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":38},"100562476","phase-4-systemic-oral-glucocorticoids-for-the-treatment-of-acute-osteoarthritis-pain-in-the-emergency-department-100562476","NCT06603662","Systemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department","Inclusion Criteria:\n\n* Age ≥18 years\n* Acute monoarticular arthritic joint pain affecting native knee, hip, or shoulder presumed to be related to osteoarthritis\n* Acute pain above baseline starting less than 72 hour prior to ED visit\n* Planned discharge from the ED\n* History of osteoarthritis of the affected joint based on radiography performed at index visit or prior available imaging\n\nExclusion Criteria:\n\n* Trauma to the affected joint within 30 days\n* Injection of affected joint within 60 days\n* Prior arthroplasty of the affected joint\n* History of coronary artery disease, severe gastrointestinal bleeding, gastric\u002Fpeptic ulcer disease, chronic kidney disease with GFR less than 30, or platelet disorders (including von Willebrand disease, hemophilia, severe thrombocytopenia with platelets less than 50 k\u002FmcL)\n* Joint pain suspected to be related to rheumatoid arthritis, gout, septic arthritis, or other non-osteoarthritis autoimmune\u002Finflammatory\u002Finfectious arthritis\n* Chronic\u002Fbaseline use of glucocorticoids (greater than 5 mg daily prednisone or equivalent within previous 7 days) or NSAIDs (daily use for more than 2 days prior to presentation)\n* Daily prescription opioid use or active opioid use disorder\n* Illicit drug use\n* Known allergy\u002Fintolerance to ibuprofen\u002FNSAIDs, prednisone, dexamethasone, or other medication precluding ability to participate in one or more study arms\n* Other contraindications to ibuprofen\u002FNSAIDs or glucocorticoids\n* Planned hospitalization from the ED\n* Pregnancy\n* Incarceration\n* Inability to provide informed consent\n* Other conditions that would preclude compliance with the study protocol and medication dosing",{"count":120,"type":20},192,[122],"PHASE4","The purpose of this clinical trial is to compare the analgesic effects (relief of pain) of glucocorticoids (steroids) and pain medication versus pain medication alone in adult patients presenting to the emergency department with joint pain due to osteoarthritis. Steroids are drugs that can reduce inflammation and are used commonly for many different medical conditions.\n\nIn brief, the central aims of the study are to:\n\n1. Assess the efficacy of adding oral glucocorticoid medications to the standard pain medications used to treat the pain of osteoarthritis.\n2. Assess the safety and tolerability of oral glucocorticoid medication for the short-term treatment of osteoarthritis pain.\n\nWe hypothesize that: 1) The addition of glucocorticoids to standard pain medications will improve reported pain scores at 3 days following the initiation of treatment compared to standard pain medications alone and 2) The use of glucocorticoids will be well tolerated.\n\nParticipants in the study will be randomized (like flipping a coin) into one of three groups:\n\n1. Study Group 1 (Control) receiving placebo pills (no active ingredient) once a day for 5 days, plus ibuprofen (pain medication) for 5 days.\n2. Study Group 2 (Intervention A) who will receive prednisone (steroid) once a day for 5 days, plus ibuprofen (pain medication) for 5 days.\n3. Study Group 3 (Intervention B) who will receive one dose of dexamethasone (steroid) followed by placebo pills (no active ingredient) once a day for 4 days, plus ibuprofen (pain medication) for 5 days.\n\nIn all groups, acetaminophen (a different pain medication) can be taken as needed for pain that is not controlled with ibuprofen.\n\nParticipants will:\n\n* Receive follow up phone calls at 1, 3, 7 and 14 days.\n* Report pain scores related to joint pain.\n* Report the number of pills taken of the various medications used in the study.\n* Report any adverse events incurred during the follow up period.",[125,126,127,128],"Osteoarthritis","Osteoarthritis (OA) of the Knee","Osteoarthritis (OA) of the Shoulder","Osteoarthritis (OA) of the Hip",[130,131,132,133],"osteoarthritis","acute pain","glucocorticosteroids","emergency department","2025-03-26",{"date":136,"type":30},"2025-03-27",{"date":138,"type":30},"2025-02-24",{"date":140,"type":20},"2027-12",{"name":36,"class":37},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":148,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":99,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":164,"locationsCount":38},"100406295","use-of-an-intrauterine-manipulator-and-its-correlation-with-positive-peritoneal-cytology-in-early-stage-endometrial-cancers-100406295","NCT04570553","Use of an Intrauterine Manipulator and Its Correlation with Positive Peritoneal Cytology in Early Stage Endometrial Cancers","Inclusion Criteria:\n\n* Subjects age 18 or older able to give informed consent\n* Biopsy diagnosed endometrial cancer (including endometrioid, serous, mucinous and clear cell histologies)\n* Planned standard of care surgical management of early stage endometrial cancer\n* No clinical evidence of disseminated intraperitoneal disease\n\nExclusion Criteria:\n\n* Final pathology does not reflect diagnosis of endometrial cancer (including endometrioid, serous, mucinous, and clear cell histology)\n* Evidence of disseminated intraperitoneal disease\n* Subject is not a surgical candidate\n* Subject elects for fertility sparing or non-operative management\n* Subject is unable to provide informed consent","FEMALE",{"count":150,"type":20},350,[101],"This study aims to answer whether use of a Vcare® intrauterine manipulator leads to an increased incidence of positive peritoneal cytology in patients undergoing surgical management of early stage (FIGO stage I\u002FII) endometrial cancer.",[154],"Endometrial Cancer",[156,157],"endometrial cancer","peritoneal cytology","2025-03-24",{"date":160,"type":30},"2025-03-28",{"date":162,"type":30},"2020-10-15",{"date":111,"type":20},{"name":36,"class":37},""]